IP Library Granted Patent US 9,161,955
Granted Patent B2
US 9,161,955 · App. 13/802,359 · Granted Oct 20, 2015

Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition

Inventors: Scheffer Tseng (Pinecrest, FL); Hua He (Miami, FL); Wei Li (Shenzhen, CN)
Assignee: TISSUETECH, INC.
A61K35/50A61K35/48A61K38/1709A61K38/39A61K38/4886C07K14/4702C07K14/4718C07K14/78C07K14/8114
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,161,955
App. No.
13/802,359
Granted
Oct 20, 2015
Kind
B2
Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Claims (12)

1. A method of inhibiting or reversing scar formation in an individual in need thereof, comprising administering a ground or pulverized amniotic membrane derived from a frozen or previously frozen placental material.

2. The method of claim 1 , wherein the ground or pulverized amniotic membrane is in the form of a homogenate.

3. The method of claim 1 , wherein the ground or pulverized amniotic membrane is in the form of a dry powder, liquid or suspension.

4. The method of claim 1 , wherein the placental material is placenta.

5. The method of claim 1 , wherein the amniotic membrane is human amniotic membrane, bovine amniotic membrane, or porcine amniotic membrane.

6. A method of inhibiting or reversing scar formation in an individual in need thereof, comprising administering a composition comprising a ground or pulverized amniotic membrane derived from a frozen or previously frozen placental material.

7. The method of claim 6 , wherein the placental material is placenta.

8. The method of claim 6 , wherein the composition further comprises a pharmaceutically-acceptable excipient.

9. The method of claim 6 , wherein the composition is a non-solid dosage form.

10. The method of claim 9 , wherein the composition is a solution, suspension, paste, ointment, oil, emulsion, cream, lotion, gel, patch, stick, balm, or shampoo.

11. The method of claim 6 , wherein the composition is an ophthalmic composition.

12. The method of claim 6 , wherein the composition is a topical composition.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
CHANGE OF NAME Recorded May 22, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063713/0329 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 030227 FRAME: 0537. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 1, 2015
From: BIO-TISSUE, INC.
To: TISSUETECH, INC.
Reel/Frame 036517/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2013
From: BIO-TISSUE, INC.
To: TISSUE TECH, INC.
Reel/Frame 030227/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2013
From: TSENG, SCHEFFER; HE, HUA; LI, WEI
To: BIO-TISSUE, INC.
Reel/Frame 030227/0457 →
Continuity (4)
Continuation 13453765 · Apr 23, 2012
Continuation 11528902 · Sep 27, 2006
Provisional Application 60720760 · Sep 27, 2005
Related Publication 20130195994A1 · Aug 1, 2013